Abstract
Expression of CD80 or CD86 costimulatory molecules on tumor cells can produce rejection of immunogenic but not poorly immunogenic tumors. We have previously shown that anti-CD3 single-chain antibodies expressed on the surface of cells can directly activate T cells. We therefore investigated whether anti-CD3 “receptors” could enhance CD86-mediated rejection of poorly immunogenic tumors. Expression of anti-CD3 receptors on cells was increased by introduction of membrane-proximal “spacer” domains containing glycosylation sites between the single-chain antibody and the transmembrane domain of the chimeric receptors. Removal of glycosylation sites in the spacer reduced surface expression due to increased shedding of chimeric receptors from the cell surface. Induction of T-cell proliferation by anti-CD3 receptors did not correlate with the expression level of chimeric protein, but rather depended on the physical properties of the spacer. Anti-CD3 receptors effectively induced T-cell cytotoxicity, whereas coexpression with CD80 or CD86 was required for generating T-cell proliferation and IL-2 secretion. Although expression of CD86 did not significantly delay the growth of poorly immunogenic B16-F1 tumors, expression of anti-CD3 receptors with CD86 produced complete tumor rejections in 50% of mice and induced significant protection against wild-type B16-F1 tumor cells. Our results show that spacer domains can dramatically influence the surface expression and the biological activity of chimeric antibody receptors. The strong antitumor activity produced by anti-CD3 receptors and CD86 on tumor cells indicates that this strategy may be beneficial for the gene-mediated therapy of poorly immunogenic tumors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- 2C11:
-
anti-CD3 antibody
- γ 1 :
-
H–CH2–CH3 region of human IgG1
- AFP:
-
alpha fetoprotein
- phOx:
-
4-ethoxymethylene-2-phenyl-2-oxazolin-5-one
- scFv:
-
single-chain antibody
- TM:
-
transmembrane domain
References
Abken H, Hombach A, Heuser C, et al. Tuning tumor-specific T-cell activation: a matter of costimulation? Trends Immunol. 2002;23:240–245.
McHugh RS, Ahmed SN, Wang YC, et al. Construction, purification, and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80). Proc Natl Acad Sci USA. 1995;92:8059–8063.
Freeman GJ, Borriello F, Hodes RJ, et al. Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production. J Exp Med. 1993;178:2185–2192.
Lenschow DJ, Walunas TL, Bluestone JA . CD28/B7 system of T cell costimulation. Ann Rev Immunol. 1996;14:233–258.
Hayakawa M, Kawaguchi S, Ishii S, et al. B7-1-transfected tumor vaccine counteracts chemotherapy-induced immunosuppression and prolongs the survival of rats bearing highly metastatic osteosarcoma cells. Int J Cancer. 1997;71:1091–1102.
Martin BK, Frelinger JG, Ting JP . Combination gene therapy with CD86 and the MHC class II transactivator in the control of lung tumor growth. J Immunol. 1999;162:6663–6670.
Fujii H, Inobe M, Kimura F, et al. Vaccination of tumor cells transfected with the B7-1 (CD80) gene induces the anti-metastatic effect and tumor immunity in mice. Int J Cancer. 1996;66:219–224.
Korkolopoulou P, Kaklamanis L, Pezzella F, et al. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br J Cancer. 1996;73:148–153.
Luboldt HJ, Kubens BS, Rubben H, et al. Selective loss of human leukocyte antigen class I allele expression in advanced renal cell carcinoma. Cancer Res. 1996;56:826–830.
Kaklamanis L, Townsend A, Doussis Anagnostopoulou IA, et al. Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (TAP) in colorectal cancer. Am J Pathol. 1994;145:505–509.
Vitale M, Rezzani R, Rodella L, et al. HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res. 1998;58:737–742.
Restifo NP, Marincola FM, Kawakami Y, et al. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst. 1996;88:100–108.
Paul DB, Barth RF, Yang W, et al. B7.1 expression by the weakly immunogenic F98 rat glioma does not enhance immunogenicity. Gene Therapy. 2000;7:993–999.
Chen L, McGowan P, Ashe S, et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med. 1994;179:523–532.
Liao KW, Lo YC, Roffler SR . Activation of lymphocytes by anti-CD3 single-chain antibody dimers expressed on the plasma membrane of tumor cells. Gene Therapy. 2000;7:339–347.
Paul S, Regulier E, Poitevin Y, et al. The combination of a chemokine, cytokine and TCR-based T cell stimulus for effective gene therapy of cancer. Cancer Immunol Immunother. 2002;51:645–654.
Paul S, Regulier E, Rooke R, et al. Tumor gene therapy by MVA-mediated expression of T-cell-stimulating antibodies. Cancer Gene Ther. 2002;9:470–477.
Liao KW, Chou WC, Lo YC, et al. Design of transgenes for efficient expression of active chimeric proteins on mammalian cells. Biotechnol Bioeng. 2001;73:313–323.
Chou WC, Liao KW, Lo YC, et al. Expression of chimeric monomer and dimer proteins on the plasma membrane of mammalian cells. Biotechnol Bioeng. 1999;65:160–169.
Groh V, Wu J, Yee C, et al. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002;419:734–738.
Reddy P, Caras I, Krieger M . Effects of O-linked glycosylation on the cell surface expression and stability of decay-accelerating factor, a glycophospholipidanchored membrane protein. J Biol Chem. 1989;264:17329–17336.
Ludwig A, Ehlert JE, Flad HD, et al. Identification of distinct surface-expressed and intracellular CXC-chemokine receptor 2 glycoforms in neutrophils: N-glycosylation is essential for maintenance of receptor surface expression. J Immunol. 2000;165:1044–1052.
Workman P, Twentyman P, Balkwill F, et al. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). Br J Cancer. 1998;77:1–10.
de Ines C, Cochlovius B, Schmidt S, et al. Apoptosis of a human melanoma cell line specifically induced by membrane-bound single-chain antibodies. J Immunol. 1999;163:3948–3956.
Winberg G, Grosmaire LS, Klussman K, et al. Surface expression of CD28 single chain Fv for costimulation by tumor cells. Immunol Rev. 1996;153:209–223.
Ye Z, Hellstrom I, Hayden-Ledbetter M, et al. Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB. Nat Med. 2002;8:343–348.
Hwang KW, Sweatt WB, Brown IE, et al. Cutting edge: targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells. J Immunol. 2002;169:633–637.
Graf MR, Jadus MR, Hiserodt JC, et al. Development of systemic immunity to glioblastoma multiforme using tumor cells genetically engineered to express the membrane-associated isoform of macrophage colony-stimulating factor. J Immunol. 1999;163:5544–5551.
Nagarajan S, Selvaraj P . Glycolipid-anchored IL-12 expressed on tumor cell surface induces antitumor immune response. Cancer Res. 2002;62:2869–2874.
Marais R, Spooner RA, Stribbling SM, et al. A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy. Nat Biotechnol. 1997;15:1373–1377.
Stabila PF, Wong SC, Kaplan FA, et al. Cell surface expression of a human IgG Fc chimera activates macrophages through Fc receptors. Nat Biotechnol. 1998;16:1357–1360.
Gruel N, Fridman WH, Teillaud JL . Bypassing tumor-specific and bispecific antibodies: triggering of antitumor immunity by expression of anti-Fc gammaR scFv on cancer cell surface. Gene Therapy. 2001;8:1721–1728.
Blochberger TC, Sabatine JM, Lee YC, et al. O-linked glycosylation of rat renal gamma-glutamyltranspeptidase adjacent to its membrane anchor domain. J Biol Chem. 1989; 264: 20718–20722.
Arribas J, Coodly L, Vollmer P, et al. Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors. J Biol Chem. 1996;271:11376–11382.
Mullberg J, Rauch CT, Wolfson MF, et al. Further evidence for a common mechanism for shedding of cell surface proteins. FEBS Lett. 1997;401:235–238.
Kajita M, Itoh Y, Chiba T, et al. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol. 2001;153:893–904.
Wedrychowski A, Kim YW, Chang TW . Immune enhancers composed of polyvalent binding sites of anti-CD3 antibodies. Biotechnology (NY). 1993;11:486–489.
Hirsch R, Bluestone JA, DeNenno L, et al. Anti-CD3 F(ab′)2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb. Transplantation. 1990;49:1117–1123.
Vossen AC, Tibbe GJ, Kroos MJ, et al. Fc receptor binding of anti-CD3 monoclonal antibodies is not essential for immunosuppression, but triggers cytokine-related side effects. Eur J Immunol. 1995;25:1492–1496.
Anton van der Merwe P, Davis SJ, Shaw AS, et al. Cytoskeletal polarization and redistribution of cell-surface molecules during T cell antigen recognition. Semin Immunol. 2000;12:5–21.
van der Merwe PA . The TCR triggering puzzle. Immunity. 2001;14:665–668.
Seliger B, Cabrera T, Garrido F, et al. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol. 2002;12:3–13.
Ochsenbein AF, Sierro S, Odermatt B, et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature. 2001;411:1058–1064.
Brentjens RJ, Latouche JB, Santos E, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med. 2003;9:279–286.
Surman DR, Dudley ME, Overwijk WW, et al. Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. J Immunol. 2000;164:562–565.
Bowman L, Grossmann M, Rill D, et al. IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood. 1998;92:1941–1949.
Schneeberger A, Koszik F, Schmidt W, et al. The tumorigenicity of IL-2 gene-transfected murine M-3D melanoma cells is determined by the magnitude and quality of the host defense reaction: NK cells play a major role. J Immunol. 1999;162:6650–6657.
Schoenberger SP, Toes RE, van der Voort EI, et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions. Nature. 1998;393:480–483.
Ridge JP, Di Rosa F, Matzinger P . A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature. 1998;393:474–478.
Bourgeois C, Rocha B, Tanchot C . A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science. 2002;297:2060–2063.
Huang AY, Golumbek P, Ahmadzadeh M, et al. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science. 1994;264:961–965.
Bai XF, Gao JX, Liu J, et al. On the site and mode of antigen presentation for the initiation of clonal expansion of CD8 T cells specific for a natural tumor antigen. Cancer Res. 2001;61:6860–6867.
thor Straten P, Becker JC, Guldberg P, et al. In situ T cells in melanoma. Cancer Immunol Immunother. 1999;48:386–395.
Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850–854.
Bloom MB, Perry-Lalley D, Robbins PF, et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med. 1997;185:453–459.
Perricone MA, Claussen KA, Smith KA, et al. Immunogene therapy for murine melanoma using recombinant adenoviral vectors expressing melanoma-associated antigens. Mol Ther. 2000;1:275–284.
Seliger B, Wollscheid U, Momburg F, et al. Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res. 2001;61:1095–1099.
Acknowledgements
We appreciate the technical assistance of Wesley Roy Balasubramanian. This study was supported by grants from the National Science Council, Taipei, Taiwan (NSC90-2318-B001-006-M51 and NSC91-3112-P001-026-Y).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Liao, KW., Chen, BM., Liu, TB. et al. Stable expression of chimeric anti-CD3 receptors on mammalian cells for stimulation of antitumor immunity. Cancer Gene Ther 10, 779–790 (2003). https://doi.org/10.1038/sj.cgt.7700637
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700637
Keywords
This article is cited by
-
The interplay between membrane topology and mechanical forces in regulating T cell receptor activity
Communications Biology (2022)
-
Adenovirus-mediated intratumoral expression of immunostimulatory proteins in combination with systemic Treg inactivation induces tumor-destructive immune responses in mouse models
Cancer Gene Therapy (2011)
-
Targeting lentiviral vector to specific cell types through surface displayed single chain antibody and fusogenic molecule
Virology Journal (2010)
-
Gene expression imaging by enzymatic catalysis of a fluorescent probe via membrane-anchored β-glucuronidase
Gene Therapy (2007)
-
Membrane-localized activation of glucuronide prodrugs by β-glucuronidase enzymes
Cancer Gene Therapy (2007)